Department of Pathology, Microbiology, and Immunology



  David W. Haas, M.D.



Professor of Medicine

Professor of Pharmacology

Professor of Pathology, Microbiology and Immunology



Contact Information



Office Location:
OHO, Suite 47183, 719 Thompson Lane, Nashville, 37204

Campus Zip - 2582
Phone: 615-936-8594

E-mail:  david.w.haas@Vanderbilt.Edu


Mailing Address:
Vanderbilt University School of Medicine
Department of Medicine

Infectious Diseases
MCN A-2200
1161 21st Ave. S.

Nashville, TN 37232







M.D., Vanderbilt
B.A., Indiana



Research Keywords



AIDS; HIV; Pharmacogenomics; Tuberculosis



Research Description



David Haas is an accomplished HIV clinical trialist and leader in human pharmacogenomic research relevant to HIV infection and its therapy. He has led the design and implementation of dozens of HIV clinical trials since 1994, both single site studies and multicenter projects. He established and has led the AIDS Clinical Trials Group (ACTG) Clinical Research Site at Vanderbilt since its inception. He previously chaired the Pharmacology Committee for the AIDS Clinical Trials Group (ACTG), has led the ACTGa??s pharmacogenomics program since 2000, and in 2011 was elected to serve on the ACTG Executive Committee. He oversaw the establishment of the ACTG Human DNA Repository, and is now extending DNA banking to non-US ACTG sites in resource-limited countries in worldwide. His work with the ACTG led to the seminal observation that a frequent CYP2B6 polymorphism predicts delayed clearance of efavirenz, which largely explains increased plasma exposure among individuals of African descent, and may help predict CNS side effects and virologic response. He is PI of a substantial, collaborative, multidisciplinary R01 entitled a??Pharmacogenomics of HIV Therapya??. He is highly engaged in collaborative, multidisciplinary research with an emphasis on the importance of human genomics for antiretroviral disposition, efficacy, and toxicity. This is complemented on his extensive work on designing and implementing prospective clinical trials.






Birdwell, KA, Grady, B, Choi, L, Xu, H, Bian, A, Denny, JC, Jiang, M, Vranic, G, Basford, M, Cowan, JD, Richardson, DM, Robinson, MP, Ikizler, TA, Ritchie, MD, Stein, CM, Haas, DW. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genomics, 22(1), 32-42, 2012

Pasaniuc, B, Rohland, N, McLaren, PJ, Garimella, K, Zaitlen, N, Li, H, Gupta, N, Neale, BM, Daly, MJ, Sklar, P, Sullivan, PF, Bergen, S, Moran, JL, Hultman, CM, Lichtenstein, P, Magnusson, P, Purcell, SM, Haas, DW, Liang, L, Sunyaev, S, Patterson, N, de Bakker, PI, Reich, D, Price, AL. Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet, 44(6), 631-5, 2012

Boger, MS, Bian, A, Shintani, A, Milne, GL, Morrow, JD, Erdem, H, Mitchell, V, Haas, DW, Hulgan, T. Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy. Antivir Ther, 17(3), 485-93, 2012

Boger, MS, Hulgan, T, Haas, DW, Mitchell, V, Smith, AG, Singleton, JR, Peltier, AC. Measures of small-fiber neuropathy in HIV infection. Auton Neurosci, 169(1), 56-61, 2012

Dooley, KE, Park, JG, Swindells, S, Allen, R, Haas, DW, Cramer, Y, Aweeka, F, Wiggins, I, Gupta, A, Lizak, P, Qasba, S, van Heeswijk, R, Flexner, C, , . Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr, 59(5), 455-62, 2012

Clifford, DB, Simpson, DM, Brown, S, Moyle, G, Brew, BJ, Conway, B, Tobias, JK, Vanhove, GF, , . A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr, 59(2), 126-33, 2012

Martin, MA, Klein, TE, Dong, BJ, Pirmohamed, M, Haas, DW, Kroetz, DL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther, 91(4), 734-8, 2012

McLaren, PJ, Ripke, S, Pelak, K, Weintrob, AC, Patsopoulos, NA, Jia, X, Erlich, RL, Lennon, NJ, Kadie, CM, Heckerman, D, Gupta, N, Haas, DW, Deeks, SG, Pereyra, F, Walker, BD, de Bakker, PI, , . Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet, 2012

Almeida, CA, Bronke, C, Roberts, SG, McKinnon, E, Keane, NM, Chopra, A, Kadie, C, Carlson, J, Haas, DW, Riddler, SA, Haubrich, R, Heckerman, D, Mallal, S, John, M. Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes. J Immunol, 187(5), 2502-13, 2011

Grady, BJ, Samuels, DC, Robbins, GK, Selph, D, Canter, JA, Pollard, RB, Haas, DW, Shafer, R, Kalams, SA, Murdock, DG, Ritchie, MD, Hulgan, T, , . Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. J Acquir Immune Defic Syndr, 58(4), 363-70, 2011

Haas, DW, Kuritzkes, DR, Ritchie, MD, Amur, S, Gage, BF, Maartens, G, Masys, D, Fellay, J, Phillips, E, Ribaudo, HJ, Freedberg, KA, Petropoulos, C, Manolio, TA, Gulick, RM, Haubrich, R, Kim, P, Dehlinger, M, Abebe, R, Telenti, A, , . Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials, 12(5), 277-85, 2011

Yuan, J, Guo, S, Hall, D, Cammett, AM, Jayadev, S, Distel, M, Storfer, S, Huang, Z, Mootsikapun, P, Ruxrungtham, K, Podzamczer, D, Haas, DW, , . Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS, 25(10), 1271-80, 2011

Grady, BJ, Torstenson, ES, McLaren, PJ, DE Bakker, PI, Haas, DW, Robbins, GK, Gulick, RM, Haubrich, R, Ribaudo, H, Ritchie, MD. Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in art-na??ve actg clinical trials participants. Pac Symp Biocomput, 253-64, 2011

Hulgan, T, Haubrich, R, Riddler, SA, Tebas, P, Ritchie, MD, McComsey, GA, Haas, DW, Canter, JA. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS, 25(1), 37-47, 2011

Currier, J, Averitt Bridge, D, Hagins, D, Zorrilla, CD, Feinberg, J, Ryan, R, Falcon, R, Tennenberg, A, Mrus, J, Squires, K, , . Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med, 153(6), 349-57, 2010

Xu, H, Doan, S, Birdwell, KA, Cowan, JD, Vincz, AJ, Haas, DW, Basford, MA, Denny, JC. An automated approach to calculating the daily dose of tacrolimus in electronic health records. AMIA Summits Transl Sci Proc, 2010, 71-5, 2010

John, M, Heckerman, D, James, I, Park, LP, Carlson, JM, Chopra, A, Gaudieri, S, Nolan, D, Haas, DW, Riddler, SA, Haubrich, R, Mallal, S. Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol, 184(8), 4368-77, 2010

Ribaudo, HJ, Liu, H, Schwab, M, Schaeffeler, E, Eichelbaum, M, Motsinger-Reif, AA, Ritchie, MD, Zanger, UM, Acosta, EP, Morse, GD, Gulick, RM, Robbins, GK, Clifford, D, Haas, DW. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis, 202(5), 717-22, 2010

Smith, JP, Weller, S, Johnson, B, Nicotera, J, Luther, JM, Haas, DW. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother, 54(3), 1146-51, 2010

Canter, JA, Robbins, GK, Selph, D, Clifford, DB, Kallianpur, AR, Shafer, R, Levy, S, Murdock, DG, Ritchie, MD, Haas, DW, Hulgan, T, , , , . African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J Infect Dis, 201(11), 1703-7, 2010

Sadagopal, S, Lorey, SL, Barnett, L, Sutherland, D, Basham, R, Erdem, H, Kalams, SA, Haas, DW. Enhanced PD-1 expression by T cells in cerebrospinal fluid does not reflect functional exhaustion during chronic human immunodeficiency virus type 1 infection. J Virol, 84(1), 131-40, 2010

Haas, DW, Koletar, SL, Laughlin, L, Kendall, MA, Suckow, C, Gerber, JG, Zolopa, AR, Bertz, R, Child, MJ, Hosey, L, Alston-Smith, B, Acosta, EP, , . Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr, 50(3), 290-3, 2009

Haas, DW, Gebretsadik, T, Mayo, G, Menon, UN, Acosta, EP, Shintani, A, Floyd, M, Stein, CM, Wilkinson, GR. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis, 199(6), 872-80, 2009

Redhage, LA, Shintani, A, Haas, DW, Emeagwali, N, Markovic, M, Oboho, I, Mwenya, C, Erdem, H, Acosta, EP, Morrow, JD, Hulgan, T. Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. HIV Clin Trials, 10(3), 181-92, 2009

Basham, RJ, Richardson, DM, Sutcliffe, CB, Haas, DW. Effect of HIV-1 infection on human DNA yield from saliva. HIV Clin Trials, 10(4), 282-5, 2009

Hulgan, T, Donahue, JP, Smeaton, L, Pu, M, Wang, H, Lederman, MM, Smith, K, Valdez, H, Pilcher, C, Haas, DW, , . Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors. Eur J Clin Pharmacol, 65(11), 1081-8, 2009

Boger, MS, Shintani, A, Redhage, LA, Mitchell, V, Haas, DW, Morrow, JD, Hulgan, T. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr, 52(4), 480-7, 2009

Pepper, T, Joseph, P, Mwenya, C, McKee, GS, Haushalter, A, Carter, A, Warkentin, J, Haas, DW, Sterling, TR. Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. Int J Tuberc Lung Dis, 12(4), 397-403, 2008

Hulgan, T, Tebas, P, Canter, JA, Mulligan, K, Haas, DW, Dub??, M, Grinspoon, S, Robbins, GK, Motsinger, AA, Kallianpur, AR, , . Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis, 197(6), 858-66, 2008

Sadagopal, S, Lorey, SL, Barnett, L, Basham, R, Lebo, L, Erdem, H, Haman, K, Avison, M, Waddell, K, Haas, DW, Kalams, SA. Enhancement of human immunodeficiency virus (HIV)-specific CD8+ T cells in cerebrospinal fluid compared to those in blood among antiretroviral therapy-naive HIV-positive subjects. J Virol, 82(21), 10418-28, 2008

Canter, JA, Haas, DW, Kallianpur, AR, Ritchie, MD, Robbins, GK, Shafer, RW, Clifford, DB, Murdock, DG, Hulgan, T. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J, 8(1), 71-7, 2008

Oswald-Richter, K, Grill, SM, Leelawong, M, Tseng, M, Kalams, SA, Hulgan, T, Haas, DW, Unutmaz, D. Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog, 3(4), e58, 2007

Motsinger, AA, Haas, DW, Hulgan, T, Ritchie, MD. Human genomic association studies: a primer for the infectious diseases specialist. J Infect Dis, 195(12), 1737-44, 2007